Effects of polyphenol compounds melanin on NAFLD/NASH prevention

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F17%3A43876014" target="_blank" >RIV/62157124:16370/17:43876014 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/17:00098633

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.biopha.2017.01.028" target="_blank" >http://dx.doi.org/10.1016/j.biopha.2017.01.028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.biopha.2017.01.028" target="_blank" >10.1016/j.biopha.2017.01.028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effects of polyphenol compounds melanin on NAFLD/NASH prevention

Popis výsledku v původním jazyce

Background: One of the pathogenic mechanisms of the progression non-alcoholic liver disease ( NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats. Methods: The study was carried out on 45 Wistar rats that were divided into 3 groups: intact, MSG-and MSG + melanin groups (n = 15 in each group). Newborn rats of MSG-and MSG + melanin groups were administered with MSG (4 mg/g, 8 mu l/g, subcutaneously) at 2nd-10th days of life. Since the age of 1 month, rats of MSG-group were treated with water (0.25 ml/100 g), rats of MSG + melanin groups-with melanin (1 mg/kg) dissolved in water (0.25 ml/100 g). Introduction: had been performed intermittently (two-week courses alternated with two-week breaks) for 3 months. In 4-month rats anthropometrical parameters and visceral adipose tissue (VAT) mass were estimated. To assess morphological changes in liver we used NAS (NAFLD activity score). The content of pro-inflammatory cytokines (interleukin (IL)-1 beta, IL-12Bp40, interferon (INF)-gamma) and anti-inflammatory cytokines (IL-4, IL-10, tumor growth factor (TGF)-beta) were measured by ELISA. Results: We found significantly lower total score (1.0 +/- 0.19 vs 3.33 +/- 0.36, p &lt; 0.001), degree of steatosis (0.73 +/- 0.18 vs 1.80 +/- 0.17, p &lt; 0.001) and manifestation of lobular inflammation (0.27 +/- 0.11 vs 1.20 +/- 0.17, p &lt; 0.001) due to NAFLD activity score in MSG + melanin group compared to MSG-obesity. NASH we confirmed only in 33.3% of rats with MSG-obesity that was significantly higher than after melanin (6.7%) administration (p = 0.033). Melanin administration reduce amount of visceral fat on 44.5% (p 0.001) as compared to MSG-obesity group. Melanin reduced the content of IL-1 beta in rat serum and restored the level of anti-inflammatory cytokines (IL-10, TGF-beta) to the control values. Conclusion: Thus, the administration of melanin can prevent development of NAFLD/NASH in rats with MSG-induced obesity and can be considered as possible novel therapeutic agents but further studies to confirm its action needed.

Název v anglickém jazyce

Effects of polyphenol compounds melanin on NAFLD/NASH prevention

Popis výsledku anglicky

Background: One of the pathogenic mechanisms of the progression non-alcoholic liver disease ( NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats. Methods: The study was carried out on 45 Wistar rats that were divided into 3 groups: intact, MSG-and MSG + melanin groups (n = 15 in each group). Newborn rats of MSG-and MSG + melanin groups were administered with MSG (4 mg/g, 8 mu l/g, subcutaneously) at 2nd-10th days of life. Since the age of 1 month, rats of MSG-group were treated with water (0.25 ml/100 g), rats of MSG + melanin groups-with melanin (1 mg/kg) dissolved in water (0.25 ml/100 g). Introduction: had been performed intermittently (two-week courses alternated with two-week breaks) for 3 months. In 4-month rats anthropometrical parameters and visceral adipose tissue (VAT) mass were estimated. To assess morphological changes in liver we used NAS (NAFLD activity score). The content of pro-inflammatory cytokines (interleukin (IL)-1 beta, IL-12Bp40, interferon (INF)-gamma) and anti-inflammatory cytokines (IL-4, IL-10, tumor growth factor (TGF)-beta) were measured by ELISA. Results: We found significantly lower total score (1.0 +/- 0.19 vs 3.33 +/- 0.36, p &lt; 0.001), degree of steatosis (0.73 +/- 0.18 vs 1.80 +/- 0.17, p &lt; 0.001) and manifestation of lobular inflammation (0.27 +/- 0.11 vs 1.20 +/- 0.17, p &lt; 0.001) due to NAFLD activity score in MSG + melanin group compared to MSG-obesity. NASH we confirmed only in 33.3% of rats with MSG-obesity that was significantly higher than after melanin (6.7%) administration (p = 0.033). Melanin administration reduce amount of visceral fat on 44.5% (p 0.001) as compared to MSG-obesity group. Melanin reduced the content of IL-1 beta in rat serum and restored the level of anti-inflammatory cytokines (IL-10, TGF-beta) to the control values. Conclusion: Thus, the administration of melanin can prevent development of NAFLD/NASH in rats with MSG-induced obesity and can be considered as possible novel therapeutic agents but further studies to confirm its action needed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedicine &amp; pharmacotherapy

ISSN

0753-3322

e-ISSN

—

Svazek periodika

88

Číslo periodika v rámci svazku

APR 2017

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

10

Strana od-do

267-276

Kód UT WoS článku

000395528000031

EID výsledku v databázi Scopus

—